NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2025. All Rights Reserved.
Date: Wednesday, April 30, 2025 9:53

Description: 2021 logo_HIPRA
Release 2.166
Vepured
Species: Pigs
Therapeutic indication: Immunological veterinary medical products: For pigs
Active ingredient: Vaccine Antigens
Product:Vepured suspension for injection in pigs
Product index: Vepured suspension for injection in pigs
Pig - meat: Zero days
Incorporating:
Qualitative and quantitative composition
Presentation
Suspension for injection for pigs.
Each dose (1 ml) contains:
Recombinant verotoxin 2e of E. coli…..RP* ≥ 1.50
*RP – relative potency (ELISA)
Adjuvant:
Aluminium hydroxide (Al 3+) 2.117 mg
DEAE-dextran 10 mg
Excipients:
Qualitative composition of excipients and other constituents
Simethicone
Sodium hydroxide
Disodium phosphate dodecahydrate
Potassium chloride
Potassium dihydrogen phosphate
Sodium chloride
Water for injections
Pharmaceutical form
Suspension for injection.
Whitish suspension
Clinical particulars
Target species
Pigs
Indications for use, specifying the target species
Active immunisation of piglets from 2 days of age to prevent mortality and reduce clinical signs of oedema disease (caused by verotoxin 2e produced by E. coli) and to reduce the loss of daily weight gain during the finishing period in the face of infections with verotoxin 2e producing E. coli until slaughter from 164 days of age.
Onset of immunity: 21 days after vaccination.
Duration of immunity:
--- For GB only: 112 days after vaccination.
--- For NI only: 16 weeks after vaccination.
Contra-indications
Do not use in case of hypersensitivity to the active substance, to the adjuvant or to any of the excipients.
Special warnings for each target species
Vaccinate healthy animals only.
Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Not applicable.
Adverse reactions (frequency and seriousness)
(For GB only; GB SPC version to date)
Pigs:
Very common adverse reactions:
Mild inflammation at the injection site (< 5 cm in diameter) that typically resolves within three days post-vaccination without treatment.
Mild depression during the day of vaccination.
Temperature rise of maximum 1.1 °C was observed. Temperatures returned to normal within 24 hrs.
Emesis, recumbency, convulsion, lethargy and loss of consciousness occur in very rare occasions within a few minutes after vaccination. The animals mostly start to recover within around 15 minutes. In case of severe anaphylactic-type reactions appropriate treatment is recommended.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals treated displaying adverse reaction(s))
common (more than 1 but less than 10 animals in 100 animals treated)
uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
rare (more than 1 but less than 10 animals in 10,000 animals treated)
very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
--- (end of GB only segment)---
(For NI only; NI SPC version to date)
Pigs:
Very common
(> 1 animal / 10 animals treated):
Injection site inflammation1
Depression2, Elevated temperature3
Very rare
(< 1 animal / 10,000 animals treated, including isolated reports):
Hypersensitivity reaction (e.g. Emesis, recumbency, convulsion, lethargy and loss of consciousness)4
1Mild inflammation at the injection site (< 5 cm in diameter) that typically resolves within three days post-vaccination without treatment.
2Mild depression during the day of vaccination.
3Temperature rise of maximum 1.1 °C was observed. Temperatures returned to normal within 24 hrs.
4 Hypersensitivity reactions may occur within a few minutes after vaccination. The animals mostly start to recover within around 15 minutes. In case of severe anaphylactic-type reactions appropriate treatment is recommended.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
--- (end of NI only segment)--- The following text applies to all UK.
Use during pregnancy and lactation
The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
Pregnancy and lactation: The use is not recommended during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Amounts to be administered and administration route
Intramuscular use.
Allow the vaccine to reach room temperature (15-25°C) before administration.
Shake well before use.
Administer a single intramuscular injection of 1 ml in the neck muscles.
Overdose
No information is available.
Withdrawal period(s)
Zero days
Pharmacological particulars
IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for Suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia).
ATC vet code: QI09AB02.
The vaccine consisting of recombinant verotoxin 2e stimulates an active immunity against VT2e toxin produced by the causative agent of oedema disease in pigs. Vaccinated animals are able to neutralise the VT2e toxin.
Pharmaceutical particulars
List of excipients
- Aluminium hydroxide
- DEAE-dextran
- Simethicone
- Sodium hydroxide
- Disodium phosphate dodecahydrate
- Potassium dihydrogen phosphate
- Sodium Chloride
- Water for injections
Major incompatibilities
Do not mix with any other veterinary product.
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 36 months.
Shelf life after first opening the immediate packaging: 10 hours.
Special precautions for storage
Store and transport refrigerated (2°C – 8°C).
Do not freeze.
Protect from light.
Nature and composition of immediate packaging
Polyethylene (PET) vials of 10, 50, 100 and 250 ml.
The vials are closed with a bromobutyl rubber stopper and aluminium cap.
Cardboard box with 1 vial of 10 doses (10 ml).
Cardboard box with 10 vials of 10 doses (10 ml).
Cardboard box with 1 vial of 50 doses (50 ml).
Cardboard box with 1 vial of 100 doses (100 ml).
Cardboard box with 1 vial of 250 doses (250 ml).
Not all pack sizes may be marketed.
Special precations
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
LABORATORIOS HIPRA, S.A
Avda. la Selva, 135
17170 Amer (Girona)
SPAIN
E-mail: hipra@hipra.com
Marketing Authorisation Number
UK(GB): Vm 17533/5012
UK (NI): EU/2/17/214/001-005
Significant changes
Date of the first authorisation or date of renewal
October 2017
Date of revision of the text
March 2022
Any other information
Further information The vaccine consisting of recombinant verotoxin 2e stimulates an active immunity against VT2e toxin produced by the causative agent of oedema disease in pigs. Vaccinated animals are able to neutralise the VT2e toxin.
Legal category
Legal category: POM-V
GTIN
GTIN description:807629 VEPURED PET UK/IE 10 ds#8
GTIN:8427711179306
GTIN description:807630 VEPURED PET UK/IE 50 ds#8
GTIN:8427711179313
GTIN description:807631 VEPURED PET UK/IE 100 ds#8
GTIN:8427711179320